scholarly journals Antiangiogenic Therapy as a New Strategy in the Treatment of Endometriosis? The First Case Report

2021 ◽  
Vol 8 ◽  
Author(s):  
Jean Bouquet de Joliniere ◽  
Arrigo Fruscalzo ◽  
Fathi Khomsi ◽  
Emanuela Stochino Loi ◽  
Floryn Cherbanyk ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Case Report ◽  
Animal Models ◽  
Estrogen Receptors ◽  
Metabolic Activity ◽  
Antiangiogenic Therapy ◽  
Vascular Endothelial ◽  
First Case ◽  
New Strategy ◽  
Diagnostic Biopsies

Angiogenesis plays a pivotal role in implantation and development of ectopic endometrial lesions. Thus, the potential usefulness of anti-angiogenic therapies has been speculated. Several reports describe their usefulness in animal models. Nonetheless this therapy has not been tested on humans yet. Here we report the outcome of a patient treated for a severe endometriosis with Bevacizumab (Avastin®), a monoclonal antibody directed against the vascular endothelial growth (VEGF). After a first-look laparoscopy with confirmatory biopsies was performed, three doses of Bevacizumab at 2-week intervals were administered. The therapy showed a well-tolerated profile and the prompt disappearance of the therapy-refractory chronic dysmenorrhea. A suppression of metabolic activity at the PET-scan compared to the basal one performed at diagnosis was also recorded. Furthermore, compared to the diagnostic biopsies prior the treatment, we documented a shift in the hormonal receptors profile toward a higher expression of progesterone and estrogen receptors in the endometriotic lesions.

scholarly journals Dysphonia after Bevacizumab Rechallenge: A Case Report

2015 ◽  
Vol 8 (3) ◽  
pp. 423-425 ◽  
Author(s):  
Corey A. Carter ◽  
Scott Z. Caroen ◽  
Arnold L. Oronsky ◽  
Bryan T. Oronsky
Keyword(s):  
Colorectal Cancer ◽  
Case Report ◽  
Advanced Colorectal Cancer ◽  
Vascular Endothelial ◽  
Standard Chemotherapy ◽  
Vegf Signaling ◽  
First Case ◽  
Voice Changes ◽  
Endothelial Growth Factor ◽  
Tumor Growth And Invasion

Inhibition of vascular endothelial growth factor (VEGF) signaling, an initiator of tumor angiogenesis, inhibits tumor growth and invasion. Bevacizumab, a monoclonal antibody to VEGF, in common use as an adjunct to standard chemotherapy like irinotecan in advanced colorectal cancer, also affects the normal (nontumor) vasculature. Dysphonia or voice changes have been anecdotally reported in patients that have been exposed to antiangiogenics. In this case report, we present an occurrence of severe dysphonia in a 60-year-old male with metastatic colorectal cancer after reintroduction of irinotecan and bevacizumab. To our knowledge, this is the first case of dysphonia associated with bevacizumab rechallenge.

Monoclonal antibody extravasations: Two case reports and literature review

2020 ◽  
pp. 107815522095000
Author(s):  
Alicia Rodríguez-Alarcón ◽  
David Conde-Estévez
Keyword(s):  
Monoclonal Antibody ◽  
Case Report ◽  
Literature Review ◽  
Case Reports ◽  
Rare Complication ◽  
Specific Treatment ◽  
Intravenous Chemotherapy ◽  
Chemotherapy Administration ◽  
First Case

Introduction Extravasation is a rare complication from intravenous chemotherapy administration. Literature about monoclonal antibody (MoAb) extravasations is scarce and also conflicting in how they are classified. Case report We reported two different cases of MoAb extravasations with cetuximab and nivolumab outcome respectively. The administration site appeared inflamed and patients did not report disturbances. Management and outcome: Both extravasations did not require specific treatment. General unspecific measures suffice to properly manage these extravasations and no sequels were observed after long follow-up. Both patients received all further courses of MoAb without any adverse events. Discussion To our knowledge, we reported the first case-report of nivolumab extravasation in the literature. In addition, the cetuximab extravasation management and outcome was in accordance with previously published reports. Both MoAb may be considered as non-aggressive or neutral. We reviewed published information about MoAb extravasations. In conclusion, not all MoAb should be classified in the same category when extravasated and special precautions are warranted with conjugated MoAb and bevacizumab.

scholarly journals Anti-PD-1 treatment-induced immediate central diabetes insipidus: a case report

Immunotherapy ◽  
2021 ◽  
Vol 13 (15) ◽  
pp. 1255-1260
Author(s):  
Mengxia Yu ◽  
Lirong Liu ◽  
Pengfei Shi ◽  
Hong Zhou ◽  
Shenxian Qian ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Case Report ◽  
Diabetes Insipidus ◽  
Tumor Cells ◽  
Initial Treatment ◽  
Hodgkin’S Lymphoma ◽  
Rare Complication ◽  
Central Diabetes Insipidus ◽  
Hodgkin's Lymphoma ◽  
First Case

Modulating PD-1 expression can constrain tumor growth. Hodgkin's lymphoma patients commonly express PD-L1 on tumor cells. We report the case of a 60-year-old male patient with relapsed classical Hodgkin's lymphoma who suffered from immediate-onset chill, hyperthermia and polyuria following initial treatment with sintilimab, an anti-PD-1 monoclonal antibody. The results revealed central diabetes insipidus (cDI). After 3 months of treatment with glucocorticoids and desmopressin acetate, his symptoms and the results were consistent with the resolution of cDI and the treatment course was discontinued. Diabetes insipidus is a rare complication of immunotherapeutic treatment, and this is the first case report to our knowledge to have described immediate-onset cDI caused by anti-PD-1 treatment.

The first case report of Pembrolizumab inducing thyroiditis and hypophysitis

2020 ◽  
Author(s):  
Rahman Maraqa Sima Abdel ◽  
Robert McMahon ◽  
Anusha Pinjala ◽  
Gastelum Alheli Arce ◽  
Mohsen Zena
Keyword(s):  
Case Report ◽  
First Case

Harel-Yoon syndrome: the first case report from Saudi Arabia

2020 ◽  
pp. 22-27 ◽  
Author(s):  
Alaa AlAyed ◽  
Manar Samman ◽  
Abdul Peer-Zada ◽  
Mohammed Almannai
Keyword(s):  
Saudi Arabia ◽  
Case Report ◽  
First Case

Assemblies of D-peptides for Targeting Cell Nucleolus

2019 ◽  
Author(s):  
Huaimin Wang ◽  
Zhaoqianqi Feng ◽  
Weiyi Tan ◽  
Bing Xu
Keyword(s):  
Particle Morphology ◽  
Side Chain ◽  
Mechanism Study ◽  
Structural Analogue ◽  
Hydrophobic Residues ◽  
Subcellular Organelles ◽  
First Case ◽  
New Strategy ◽  
Peptide Derivative ◽  
Peptide Nanoparticles

<p>Selectively targeting cell nucleolus remains a challenge. Here we report the first case that D-peptides form membraneless molecular condensates with RNA for targeting cell nucleolus. A D-peptide derivative, enriched with lysine and hydrophobic residues, self-assembles to form nanoparticles, which enter cells through clathrin dependent endocytosis and mainly accumulate at cell nucleolus. Structural analogue of the D-peptide reveals that particle morphology of the assemblies, which depends on the side chain modification, favors the cellular uptake. Contrasting to those of the D-peptide, the assemblies of the corresponding L-enantiomer largely localize in cell lysosomes. Preliminary mechanism study suggests that the D-peptide nanoparticles interact with RNA to form membraneless condensates in the nucleolus, which further induces DNA damage and results in cell death. This work illustrates a new strategy for rationally designing supramolecular assemblies of D-peptides for targeting subcellular organelles.</p>

Sign in / Sign up

Export Citation Format

Share Document